Gene · 2549
Papers2,374
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 2,374
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Network Dynamics Caused by Genomic Alteration Determine the Therapeutic Response to FGFR Inhibitors for Lung Cancer. | Biomolecules | 2022 | 36139037 | PubTator, text mining | PubMed |
| Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. | Cell Rep Med | 2022 | 36130479 | PubTator, text mining | PubMed |
| Malnourishment affects gene expression along the length of the small intestine. | Front Nutr | 2022 | 36118759 | PubTator, text mining | PubMed |
| Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. | Signal Transduct Target Ther | 2022 | 36115852 | PubTator, text mining | PubMed |
| An Integrated Proteomic Strategy to Identify SHP2 Substrates. | J Proteome Res | 2022 | 36103635 | PubTator, text mining | PubMed |
| Gαi protein subunit: A step toward understanding its non-canonical mechanisms. | Front Cell Dev Biol | 2022 | 36092739 | PubTator, text mining | PubMed |
| Antidepressant-like effects of trophic factor receptor signaling. | Front Mol Neurosci | 2022 | 36081576 | PubTator, text mining | PubMed |
| Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer. | Cancers (Basel) | 2022 | 36077757 | PubTator, text mining | PubMed |
| PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design. | Mol Cancer Ther | 2022 | 36066448 | PubTator, text mining | PubMed |
| High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities. | Cancer Res | 2022 | 36040373 | PubTator, text mining | PubMed |
| LncRNA DLEU1 facilitates the progression of oral squamous cell carcinoma by miR-126-5p/GAB1 axis. | Kaohsiung J Med Sci | 2022 | 36039933 | PubTator, text mining | PubMed |
| Receptor-kinase EGFR-MAPK adaptor proteins mediate the epithelial response to Candida albicans via the cytolytic peptide toxin, candidalysin. | J Biol Chem | 2022 | 36037968 | PubTator, text mining | PubMed |
| The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents. | Front Pediatr | 2022 | 36034555 | PubTator, text mining | PubMed |
| Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response. | J Hematol Oncol | 2022 | 36031605 | PubTator, text mining | PubMed |
| Prenatal overgrowth and polydramnios: Would you think about Noonan syndrome? | Clin Case Rep | 2022 | 36017115 | PubTator, text mining | PubMed |
| Expression of MicroRNAs in Sepsis-Related Organ Dysfunction: A Systematic Review. | Int J Mol Sci | 2022 | 36012630 | PubTator, text mining | PubMed |
| Carcinoma of unknown primary: Molecular tumor board-based therapy. | CA Cancer J Clin | 2022 | 36006378 | PubTator, text mining | PubMed |
| Tyrosine phosphatase SHP2 in ovarian granulosa cells balances follicular development by inhibiting PI3K/AKT signaling. | J Mol Cell Biol | 2022 | 36002018 | PubTator, text mining | PubMed |
| Protocol for stratification of triple-negative breast cancer patients using in silico signaling dynamics. | STAR Protoc | 2022 | 35990741 | PubTator, text mining | PubMed |
| Endothelial progenitor cells overexpressing Grb2-associated binder 1 for in vitro-constructed tissue-engineered heart valves. | Kardiologiia | 2022 | 35989628 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2549/papers?page=18